L3VLUP
ProSign in

GPCR in the 13F filings

Structure Therapeutics Inc · CUSIP 86366E106

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Jun 2025
the date the book describes
Filed
14 Aug 2025
latest of these filings; the earliest 13 Aug 2025
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
95
filed both Q1 2025 and Q2 2025; 2 listed it in both
Shares listed
11,770,366
combined, among listed positions
Reported value
$244m
combined, at the quarter end

Among the 95 comparable managers: 2 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +321,591.

Managers listing GPCR in Q2 2025

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2025, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Wellington Management Group LLP6,875,769$143munder 0.1%Trimmed-915,41414 Aug 2025 (the filing on sec.gov)
Janus Henderson Group Ltd4,573,006$95munder 0.1%Added+217,81214 Aug 2025 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC321,591$6.7munder 0.1%Newnew14 Aug 2025 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2025 to Q2 2025, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (1)

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 3 in Q2 2026

Tracked managers listing it, at least.

02468Q1 2023Q3 2023Q1 2024Q3 2024Q1 2025Q3 2025Q1 2026Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GPCR by quarter
QuarterHoldersReported valueBuyersSellers
Q1 20231$4.0mn.a.n.a.
Q2 20232$25mn.a.n.a.
Q3 20237$307mn.a.n.a.
Q4 20235$314m41
Q1 20245$439m40
Q2 20248$603m71
Q3 20245$738m41
Q4 20244$429m40
Q1 20253$258m21
Q2 20253$244m22
Q3 20252$284m02
Q4 20257$1.5bn1610
Q1 20265$636m1610
Q2 20263$686m914

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GPCR and LLY →GPCR and JNJ →GPCR and VRTX →Choose a stock to compare with GPCR →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GPCR, latest filings →Back to the 13F Explorer →